NasdaqGS:ACADBiotechs
ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds
Regulatory milestone in Europe puts ACADIA Pharmaceuticals stock in focus
The latest move in ACADIA Pharmaceuticals (ACAD) stock was driven by a key regulatory event, as European drug reviewers issued a positive opinion on Daybue for treating neurobehavioral symptoms of Rett syndrome.
See our latest analysis for ACADIA Pharmaceuticals.
For investors tracking the bigger picture, ACADIA Pharmaceuticals’ recent CHMP milestone comes after a mixed run, with a 16.34% 1 month share price return and...